Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Anti-cancer drug delivery method smuggles drug into cancer cell before triggering release

Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release.

12 May 2014

Shuganjieyu capsule reverses depressive behaviors by increasing brain-derived neurotrophic factor

Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Administration of China since 2008.

8 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

Study explains biological processes of malignant cancer cells

Cancer cells may be known for their uncontrollable growth and spread, but they also differ from normal tissue in another manner: how they produce energy.

22 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

16 Apr 2014

Caffeine has positive effect on tau deposits in Alzheimer's disease

As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease.

7 Apr 2014

Researchers find new drug target for mitochondrial dysfunction

Mitochondria, long known as "cellular power plants" for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions. Mitochondrial defects are often observed in a variety of diseases, including cancer, Alzheimer's disease, and Parkinson's disease, and are the hallmarks of a number of genetic mitochondrial disorders whose manifestations range from muscle weakness to organ failure. Despite a fairly strong understanding of the pathology of such genetic mitochondrial disorders, efforts to treat them have been largely ineffective.

28 Mar 2014

Monash University research offers new hope to people with heart attacks

Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.

11 Mar 2014

Metabolic profiling of liver cells suggests new treatments for cirrhosis patients

In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University-led team of researchers examined the metabolic breakdown that takes place in liver cells during late-stage cirrhosis and found clues that suggest new treatments to delay liver failure.

5 Mar 2014

H4 receptor activation plays part in NSCLC progression

Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows.

27 Feb 2014

Tissue repair drug can improve healing rates in people with diabetic foot ulcer

Patients were twice as likely to have a diabetic foot ulcer heal within eight weeks when they were treated with a tissue repair drug versus a placebo, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

27 Feb 2014

Researchers identify protein that regulates how genetic information transcribed from DNA to mRNA

Molecular biologists from Indiana University are part of a team that has identified a protein that regulates the information present in a large number of messenger ribonucleic acid molecules that are important for carrying genetic information from DNA to protein synthesis.

7 Feb 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

A multinational set of seven teams is banding together to develop a drug that may potentially fight many different cancers through an antibody that would work within the body's metabolic system.

16 Jan 2014

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Esophageal Squamous Cell Carcinoma, the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore have discovered a biomarker, called adenosine deaminase acting on RNA-1, which has the potential to improve the diagnosis, prognosis and treatment of this disease.